What drugs should be associated antialdosterone drugs?

Blocking the adverse effects of the rennin-angiotensin system has been a major focus of drug development for the treatment of cardiovascular disease over the last 30 years. Plasma aldosterone levels are only transiently decreased suppressed after the initiation of angiotensin-converting enzyme (ACE) inhibitors treatment and has been shown that aldosterone causes adverse effects on the cardiovascular system independent of angiotensin II. In two consecutive meetings, 50 experts critically reviewed the available evidence. The present document reflects the consensus of the subject: "What drugs should be associated antialdosterone drugs?" Pharmacological treatment of congestive heart failure has changed significantly in recent years. However, many adverse effects have been reported with different associations currently used not only for the treatment of left ventricular dysfunction, but also for the treatment of refractory arterial hypertension. Among them the most important is the hyperkalemia to modify pharmacologically neurohumoral axis of the renin-angiotensinaldosterone system. At present positive and negative drug associations are observed in a group of drugs aldosterone can be categorized interactions with cardiovascular and non-cardiovascular drugs.